After several beautiful years together, Daniel Bisericaru has grown out his cavity in Budapest and leaves (obviously only temporarily) CarboHyde and Hungary.
Dani was probably the most diligent among us, with an insatiable appetite for knowledge and challenge.
Wherever your road may lead you, your next place will be lucky to have you.
You are always our guest for a chimney cake and a fruit soup in Budapest 🙂
From 2026, at CarboHyde we decided to expand beyond cyclodextrin-based drug-development.
This short 2-pager captures the support we can provide locally in Hungary:
1. Drug substance development and manufacturing
2. Drug product development
3. Analytical support and CMC
4. Bioanalytical testing and toxicology
5. GMP production
6. Regulatory support
– custom synthesis
– formulation development
– analysis (of cyclodextrins and their complexes).
Learn more from Dani’s creation and get in touch if you have a problem to chat about in this field.
We are pleased to announce that Carbohyde Zrt. has received funding under the Economic Development and Innovation Operational Program Plus, specifically through the GINOP_PLUSZ-2.1.3-24 call for proposals! 🚀 The project aims to introduce innovations in the company’s manufacturing and marketing processes. As part of this, a digitally supported, partially automated manufacturing model will be implemented, increasing capacity utilization and reducing external dependencies. Additionally, a new data-driven marketing model will be developed, enabling scalable and measurable campaigns.
As part of the project, Carbohyde Zrt. has received a grant of 40,724,066 HUF. The project started on December 1, 2025, with a planned completion date of November 30, 2026.
The development is co-financed by the European Union and the Hungarian state, contributing to the increased competitiveness of the Hungarian economy. 🌍💡
Let’s Build Hungary Together! 🇭🇺
Kisléptékű innovációs beruházás a Carbohyde Zrt.-nél
Örömmel értesítjük partnereinket, hogy a Carbohyde Zrt. elnyerte a Gazdaságfejlesztési és Innovációs Operatív Program Plusz keretében meghirdetett GINOP_PLUSZ-2.1.3-24 azonosító számú pályázat támogatását! 🚀 A projekt célja, hogy a vállalkozás gyártási és marketingfolyamatai között innovációkat vezessen be. Ennek részeként digitálisan támogatott, részben automatizált gyártási modell kerül bevezetésre, amely növeli a kapacitáskihasználást és csökkenti a külső függőséget. Ezen kívül egy új, adatvezérelt marketingmodell is kialakításra kerül, amely skálázható, mérhető kampányokat tesz lehetővé.
A projekt keretében a Carbohyde Zrt. 40 724 066 Ft támogatásban részesült. A projekt kezdete 2025. december 1., a befejezés tervezett dátuma pedig 2026. november 30.
A fejlesztés az Európai Unió és a magyar állam társfinanszírozásával valósul meg, és hozzájárul a magyar gazdaság versenyképességének növeléséhez. 🌍💡
Építsük együtt Magyarországot! 🇭🇺
I love to feel proud.
Which is exactly what it felt to read the latest patent of Clinch Biosciences / Motorpharma Ltd.
Not because they use cyclodextrin (okay, a little bit of that too – HPBCD). For two main reasons:
1. The pioneering discovery and development work they are doing to treat muscle-related diseases and symptoms with myosin inhibitors. They are determined, passionate, persistent, and unique.
2. They are the exception. They showed us that it is possible to start and carry out innovative NCE development in Hungary, to form a pharma company around i,t and lead it to success.
I strongly believe their example will resonate in many other Hungarian companies and inspire us to dream big and live those dreams.
Thank you for being a model!
And for the rest, check out their website, certainly worth it. Patent in comment.
WO2026020167 INHIBITORS OF SMOOTH MUSCLE MYOSINS AND USES THEREOF
